6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
or	CC	or	or	or	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
prescribing	NN	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
:	:	:	:	:	N	O

Risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
Thyroid	NNP	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
Tumors	NNPS	tumors	tumor	tumor	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
Secretagogues	NNP	secretagogues	secretagogues	secretagogu	N	O
or	CC	or	or	or	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

Severe	JJ	severe	severe	sever	N	B-Severity
Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
Disease	NNP	disease	disease	diseas	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
are	VBP	are	are	are	N	O
:	:	:	:	:	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Eli	NNP	eli	eli	eli	N	O
Lilly	NNP	lilly	lilly	lilli	N	O
and	CC	and	and	and	N	O
Company	NNP	company	company	compani	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
LillyRx	NNP	lillyrx	lillyrx	lillyrx	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
545	CD	545	545	545	N	O
-	:	-	-	-	N	O
5979	CD	5979	5979	5979	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNS	studies	study	studi	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O

The	DT	the	the	the	N	O
data	NN	data	data	data	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
are	VBP	are	are	are	N	O
derived	VBN	derived	derived	deriv	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
[	VBD	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
data	NNS	data	data	data	N	O
reflect	VBP	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
1670	CD	1670	1670	1670	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
of	IN	of	of	of	N	O
23.8	CD	23.8	23.8	23.8	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
arms	NNS	arms	arm	arm	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
56	CD	56	56	56	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
1%	CD	1%	1%	1%	N	O
were	VBD	were	were	were	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
or	CC	or	or	or	N	O
older	JJR	older	older	older	N	O
and	CC	and	and	and	N	O
53%	CD	53%	53%	53%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
was	VBD	was	wa	wa	N	O
69%	CD	69%	69%	69%	N	O
White	NNP	white	white	white	N	O
,	,	,	,	,	N	O
7%	CD	7%	7%	7%	N	O
Black	NNP	black	black	black	N	O
or	CC	or	or	or	N	O
African	JJ	african	african	african	N	O
American	NNP	american	american	american	N	O
,	,	,	,	,	N	O
13%	CD	13%	13%	13%	N	O
Asian	JJ	asian	asian	asian	N	O
;	:	;	;	;	N	O
30%	CD	30%	30%	30%	N	O
were	VBD	were	were	were	N	O
of	IN	of	of	of	N	O
Hispanic	NNP	hispanic	hispanic	hispan	N	O
or	CC	or	or	or	N	O
Latino	NNP	latino	latino	latino	N	O
ethnicity	NN	ethnicity	ethnicity	ethnic	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
had	VBD	had	had	had	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
average	NN	average	average	averag	N	O
of	IN	of	of	of	N	O
8.0	CD	8.0	8.0	8.0	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
HbA1c	NNP	hba1c	hba1c	hba1c	Y	O
of	IN	of	of	of	N	O
8.0%	CD	8.0%	8.0%	8.0%	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
reported	VBD	reported	reported	report	N	O
retinopathy	JJ	retinopathy	retinopathy	retinopathi	Y	O
.	.	.	.	.	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
estimated	VBD	estimated	estimated	estim	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
was	VBD	was	wa	wa	N	O
normal	JJ	normal	normal	normal	N	O
or	CC	or	or	or	N	O
mildly	RB	mildly	mildly	mildli	N	O
impaired	JJ	impaired	impaired	impair	N	O
(	(	(	(	(	N	O
eGFR	JJ	egfr	egfr	egfr	N	O
60	CD	60	60	60	N	O
mL	NN	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
96.0%	CD	96.0%	96.0%	96.0%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
pooled	JJ	pooled	pooled	pool	N	O
study	NN	study	study	studi	N	O
populations	NNS	populations	population	popul	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
shows	NNS	shows	show	show	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
excluding	VBG	excluding	excluding	exclud	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
present	JJ	present	present	present	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	JJR	more	more	more	N	O
commonly	RB	commonly	commonly	commonli	N	O
on	IN	on	on	on	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
than	IN	than	than	than	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBN	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O

a	DT	a	a	a	N	O
Includes	NNP	includes	includes	includ	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fecal	JJ	fecal	fecal	fecal	N	B-AdverseReaction
volume	NN	volume	volume	volum	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
frequent	JJ	frequent	frequent	frequent	N	B-AdverseReaction
bowel	NN	bowel	bowel	bowel	N	I-AdverseReaction
movements	NNS	movements	movement	movement	N	I-AdverseReaction
.	.	.	.	.	N	O

b	NN	b	b	b	N	O
Includes	NNP	includes	includes	includ	N	O
retching	NN	retching	retching	retch	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
projectile	NN	projectile	projectile	projectil	N	I-AdverseReaction
.	.	.	.	.	N	O

c	SYM	c	c	c	N	O
Includes	VBZ	includes	includes	includ	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
lower	RBR	lower	lower	lower	N	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
tenderness	NN	tenderness	tenderness	tender	Y	I-AdverseReaction
,	,	,	,	,	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
.	.	.	.	.	N	O

d	NN	d	d	d	N	O
Includes	NNP	includes	includes	includ	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
malaise	NN	malaise	malaise	malais	Y	B-AdverseReaction
.	.	.	.	.	N	O

Note	NN	note	note	note	N	O
:	:	:	:	:	N	O
Percentages	NNS	percentages	percentage	percentag	N	O
reflect	VBP	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
that	WDT	that	that	that	N	O
reported	VBD	reported	reported	report	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
.	.	.	.	.	N	O

Adverse	NN	adverse	adverse	advers	N	O

Reaction	NN	reaction	reaction	reaction	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
568	CD	568	568	568	N	O
)	)	)	)	)	N	O
Trulicity	NN	trulicity	trulicity	trulic	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
836	CD	836	836	836	N	O
)	)	)	)	)	N	O
Trulicity	NN	trulicity	trulicity	trulic	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
834	CD	834	834	834	N	O
)	)	)	)	)	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
5.3	CD	5.3	5.3	5.3	N	O
12.4	CD	12.4	12.4	12.4	N	O
21.1	CD	21.1	21.1	21.1	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
a	DT	a	a	a	N	O
6.7	CD	6.7	6.7	6.7	N	O
8.9	CD	8.9	8.9	8.9	N	O
12.6	CD	12.6	12.6	12.6	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
b	NN	b	b	b	N	O
2.3	CD	2.3	2.3	2.3	N	O
6.0	CD	6.0	6.0	6.0	N	O
12.7	CD	12.7	12.7	12.7	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
c	VBD	c	c	c	N	O
4.9	CD	4.9	4.9	4.9	N	O
6.5	CD	6.5	6.5	6.5	N	O
9.4	CD	9.4	9.4	9.4	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Appetite	NNP	appetite	appetite	appetit	N	I-AdverseReaction
1.6	CD	1.6	1.6	1.6	N	O
4.9	CD	4.9	4.9	4.9	N	O
8.6	CD	8.6	8.6	8.6	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
2.3	CD	2.3	2.3	2.3	N	O
4.1	CD	4.1	4.1	4.1	N	O
5.8	CD	5.8	5.8	5.8	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
d	VBD	d	d	d	N	O
2.6	CD	2.6	2.6	2.6	N	O
4.2	CD	4.2	4.2	4.2	N	O
5.6	CD	5.6	5.6	5.6	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

In	IN	in	in	in	N	O

the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
placebo	JJ	placebo	placebo	placebo	N	O
21.3%	CD	21.3%	21.3%	21.3%	N	O
,	,	,	,	,	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
31.6%	CD	31.6%	31.6%	31.6%	N	O
,	,	,	,	,	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
41.0%	CD	41.0%	41.0%	41.0%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

More	JJR	more	more	more	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
TRULICITY	$	trulicity	trulicity	trulic	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
3.5%	CD	3.5%	3.5%	3.5%	N	O
)	)	)	)	)	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
than	IN	than	than	than	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Investigators	NNS	investigators	investigator	investig	N	O
graded	VBD	graded	graded	grade	N	O
the	DT	the	the	the	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
occurring	VBG	occurring	occurring	occur	N	O
on	IN	on	on	on	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NNS	mg	mg	mg	N	O
and	CC	and	and	and	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
as	IN	as	a	as	N	O
"	NNP	"	"	"	N	O
mild	VBP	mild	mild	mild	N	B-Severity
"	NNP	"	"	"	N	O
in	IN	in	in	in	N	O
58%	CD	58%	58%	58%	N	O
and	CC	and	and	and	N	O
48%	CD	48%	48%	48%	N	O
of	IN	of	of	of	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
"	JJ	"	"	"	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
"	NN	"	"	"	N	O
in	IN	in	in	in	N	O
35%	CD	35%	35%	35%	N	O
and	CC	and	and	and	N	O
42%	CD	42%	42%	42%	N	O
of	IN	of	of	of	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
"	VB	"	"	"	N	O
severe	JJ	severe	severe	sever	N	B-Severity
"	NN	"	"	"	N	O
in	IN	in	in	in	N	O
7%	CD	7%	7%	7%	N	O
and	CC	and	and	and	N	O
11%	CD	11%	11%	11%	N	O
of	IN	of	of	of	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
frequencies	NNS	frequencies	frequency	frequenc	N	O
listed	VBN	listed	listed	list	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
:	:	:	:	:	N	O
placebo	NN	placebo	placebo	placebo	N	O
;	:	;	;	;	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
;	:	;	;	;	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
,	,	,	,	,	N	O
3.9%	CD	3.9%	3.9%	3.9%	N	O
,	,	,	,	,	N	O
3.7%	CD	3.7%	3.7%	3.7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
flatulence	NN	flatulence	flatulence	flatul	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.4%	CD	1.4%	1.4%	1.4%	N	O
,	,	,	,	,	N	O
1.4%	CD	1.4%	1.4%	1.4%	N	O
,	,	,	,	,	N	O
3.4%	CD	3.4%	3.4%	3.4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
distension	NN	distension	distension	distens	N	I-AdverseReaction
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
,	,	,	,	,	N	O
2.9%	CD	2.9%	2.9%	2.9%	N	O
,	,	,	,	,	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
gastroesophageal	JJ	gastroesophageal	gastroesophageal	gastroesophag	N	B-AdverseReaction
reflux	NN	reflux	reflux	reflux	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
,	,	,	,	,	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
,	,	,	,	,	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
eructation	NN	eructation	eructation	eruct	Y	B-AdverseReaction
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
,	,	,	,	,	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
,	,	,	,	,	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
Active	NNP	active	active	activ	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O

The	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
larger	JJR	larger	larger	larger	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
type	JJ	type	type	type	N	O
2	CD	2	2	2	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
participating	VBG	participating	participating	particip	N	O
in	IN	in	in	in	N	O
6	CD	6	6	6	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
evaluating	VBG	evaluating	evaluating	evalu	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
as	IN	as	a	as	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
and	CC	and	and	and	N	O
add	VB	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
to	TO	to	to	to	N	O
oral	JJ	oral	oral	oral	N	O
medications	NNS	medications	medication	medic	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
pool	NN	pool	pool	pool	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
3342	CD	3342	3342	3342	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
type	JJ	type	type	type	N	O
2	CD	2	2	2	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
52	CD	52	52	52	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
56	CD	56	56	56	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
2%	CD	2%	2%	2%	N	O
were	VBD	were	were	were	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
or	CC	or	or	or	N	O
older	JJR	older	older	older	N	O
and	CC	and	and	and	N	O
51%	CD	51%	51%	51%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
was	VBD	was	wa	wa	N	O
71%	CD	71%	71%	71%	N	O
White	NNP	white	white	white	N	O
,	,	,	,	,	N	O
7%	CD	7%	7%	7%	N	O
Black	NNP	black	black	black	N	O
or	CC	or	or	or	N	O
African	JJ	african	african	african	N	O
American	NNP	american	american	american	N	O
,	,	,	,	,	N	O
11%	CD	11%	11%	11%	N	O
Asian	JJ	asian	asian	asian	N	O
;	:	;	;	;	N	O
32%	CD	32%	32%	32%	N	O
were	VBD	were	were	were	N	O
of	IN	of	of	of	N	O
Hispanic	NNP	hispanic	hispanic	hispan	N	O
or	CC	or	or	or	N	O
Latino	NNP	latino	latino	latino	N	O
ethnicity	NN	ethnicity	ethnicity	ethnic	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
had	VBD	had	had	had	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
average	NN	average	average	averag	N	O
of	IN	of	of	of	N	O
8.2	CD	8.2	8.2	8.2	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
HbA1c	NNP	hba1c	hba1c	hba1c	Y	O
of	IN	of	of	of	N	O
7.6	CD	7.6	7.6	7.6	N	O
-	:	-	-	-	N	O
8.5%	CD	8.5%	8.5%	8.5%	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
5.2%	CD	5.2%	5.2%	5.2%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
reported	VBD	reported	reported	report	N	O
retinopathy	JJ	retinopathy	retinopathy	retinopathi	Y	O
.	.	.	.	.	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
estimated	VBD	estimated	estimated	estim	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
was	VBD	was	wa	wa	N	O
normal	JJ	normal	normal	normal	N	O
or	CC	or	or	or	N	O
mildly	RB	mildly	mildly	mildli	N	O
impaired	JJ	impaired	impaired	impair	N	O
(	(	(	(	(	N	O
eGFR	JJ	egfr	egfr	egfr	N	O
60	CD	60	60	60	N	O
ml	NN	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m2	NN	m2	m2	m2	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
95.7%	CD	95.7%	95.7%	95.7%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
population	NN	population	population	popul	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
types	NNS	types	type	type	N	O
and	CC	and	and	and	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
excluding	VBG	excluding	excluding	exclud	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
summarizes	VBZ	summarizes	summarizes	summar	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
documented	VBN	documented	documented	document	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
(	(	(	(	(	N	O
70	CD	70	70	70	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
glucose	VBP	glucose	glucose	glucos	Y	O
threshold	NN	threshold	threshold	threshold	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	I-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Incidence	NNP	incidence	incidence	incid	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
Documented	NNP	documented	documented	document	N	O
Symptomatic	NNP	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
and	CC	and	and	and	N	O
Severe	NNP	severe	severe	sever	N	B-Severity
Hypoglycemia	NNP	hypoglycemia	hypoglycemia	hypoglycemia	Y	I-AdverseReaction
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Metformin	NNP	metformin	metformin	metformin	N	O

(	(	(	(	(	N	O
26	CD	26	26	26	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
N	VBP	n	n	n	N	O
177	CD	177	177	177	N	O
N	NNP	n	n	n	N	O
302	CD	302	302	302	N	O
N	NNP	n	n	n	N	O
304	CD	304	304	304	N	O

Documented	VBN	documented	documented	document	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
2.6%	CD	2.6%	2.6%	2.6%	N	O
5.6%	CD	5.6%	5.6%	5.6%	N	O

Severe	RB	severe	severe	sever	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Pioglitazone	NNP	pioglitazone	pioglitazone	pioglitazon	N	O

(	(	(	(	(	N	O
26	CD	26	26	26	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
N	VBP	n	n	n	N	O
141	CD	141	141	141	N	O
N	NNP	n	n	n	N	O
280	CD	280	280	280	N	O
N	NNP	n	n	n	N	O
279	CD	279	279	279	N	O

Documented	VBN	documented	documented	document	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
1.4%	CD	1.4%	1.4%	1.4%	N	O
4.6%	CD	4.6%	4.6%	4.6%	N	O
5.0%	CD	5.0%	5.0%	5.0%	N	O

Severe	RB	severe	severe	sever	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
when	WRB	when	when	when	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
was	VBD	was	wa	wa	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
sulfonylurea	NN	sulfonylurea	sulfonylurea	sulfonylurea	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Documented	VBN	documented	documented	document	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
39%	CD	39%	39%	39%	N	O
and	CC	and	and	and	N	O
40%	CD	40%	40%	40%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
when	WRB	when	when	when	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
co	VBN	co	co	co	N	O
-	:	-	-	-	N	O
administered	VBN	administered	administered	administ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
sulfonylurea	NN	sulfonylurea	sulfonylurea	sulfonylurea	N	O
.	.	.	.	.	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0%	CD	0%	0%	0%	N	O
and	CC	and	and	and	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
when	WRB	when	when	when	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
co	VBN	co	co	co	N	O
-	:	-	-	-	N	O
administered	VBN	administered	administered	administ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
sulfonylurea	NN	sulfonylurea	sulfonylurea	sulfonylurea	N	O
.	.	.	.	.	N	O

Documented	VBN	documented	documented	document	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
85%	CD	85%	85%	85%	N	O
and	CC	and	and	and	N	O
80%	CD	80%	80%	80%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
when	WRB	when	when	when	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
co	VBN	co	co	co	N	O
-	:	-	-	-	N	O
administered	VBN	administered	administered	administ	N	O
with	IN	with	with	with	N	O
prandial	JJ	prandial	prandial	prandial	N	O
insulin	NN	insulin	insulin	insulin	Y	O
.	.	.	.	.	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2.4%	CD	2.4%	2.4%	2.4%	N	O
and	CC	and	and	and	N	O
3.4%	CD	3.4%	3.4%	3.4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
when	WRB	when	when	when	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
co	VBN	co	co	co	N	O
-	:	-	-	-	N	O
administered	VBN	administered	administered	administ	N	O
with	IN	with	with	with	N	O
prandial	JJ	prandial	prandial	prandial	N	O
insulin	NN	insulin	insulin	insulin	Y	O
.	.	.	.	.	N	O

Heart	NN	heart	heart	heart	N	O

Rate	NNP	rate	rate	rate	N	O
Increase	NNP	increase	increase	increas	N	O
and	CC	and	and	and	N	O
Tachycardia	NNP	tachycardia	tachycardia	tachycardia	Y	O
Related	NNP	related	related	relat	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

TRULICITY	$	trulicity	trulicity	trulic	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
(	(	(	(	(	N	O
HR	NNP	hr	hr	hr	N	I-AdverseReaction
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
beats	NNS	beats	beat	beat	N	O
per	IN	per	per	per	N	O
minute	NN	minute	minute	minut	N	O
(	(	(	(	(	N	O
bpm	NN	bpm	bpm	bpm	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
clinical	JJ	clinical	clinical	clinic	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
HR	NNP	hr	hr	hr	N	I-AdverseReaction
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
sinus	JJ	sinus	sinus	sinu	N	B-AdverseReaction
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
.	.	.	.	.	N	O

Sinus	NNP	sinus	sinus	sinu	N	B-AdverseReaction
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
3.0%	CD	3.0%	3.0%	3.0%	N	O
,	,	,	,	,	N	O
2.8%	CD	2.8%	2.8%	2.8%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
5.6%	CD	5.6%	5.6%	5.6%	N	O
of	IN	of	of	of	N	O
patient	NN	patient	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Persistence	NN	persistence	persistence	persist	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
sinus	JJ	sinus	sinus	sinu	N	I-AdverseReaction
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	I-AdverseReaction
(	(	(	(	(	N	O
reported	VBN	reported	reported	report	N	O
at	IN	at	at	at	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
2	CD	2	2	2	N	O
visits	NNS	visits	visit	visit	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
,	,	,	,	,	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
and	CC	and	and	and	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Episodes	NNS	episodes	episode	episod	N	O
of	IN	of	of	of	N	O
sinus	JJ	sinus	sinus	sinu	N	B-AdverseReaction
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	I-AdverseReaction
,	,	,	,	,	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	I-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
of	IN	of	of	of	N	O
15	CD	15	15	15	N	O
beats	NNS	beats	beat	beat	N	O
per	IN	per	per	per	N	O
minute	NN	minute	minute	minut	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
,	,	,	,	,	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
and	CC	and	and	and	N	O
2.2%	CD	2.2%	2.2%	2.2%	N	O
of	IN	of	of	of	N	O
patient	NN	patient	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

Across	IN	across	across	across	N	O
four	CD	four	four	four	N	O
Phase	NN	phase	phase	phase	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
five	CD	five	five	five	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
64	CD	64	64	64	N	O
(	(	(	(	(	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
)	)	)	)	)	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
developed	VBD	developed	developed	develop	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
drug	NN	drug	drug	drug	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
(	(	(	(	(	N	O
ADAs	NNP	adas	ada	ada	N	O
)	)	)	)	)	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
active	JJ	active	active	activ	N	O
ingredient	NN	ingredient	ingredient	ingredi	N	O
in	IN	in	in	in	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
(	(	(	(	(	N	O
i	NN	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
dulaglutide	NN	dulaglutide	dulaglutide	dulaglutid	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
64	CD	64	64	64	N	O
dulaglutide	NN	dulaglutide	dulaglutide	dulaglutid	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
that	WDT	that	that	that	N	O
developed	VBD	developed	developed	develop	N	O
dulaglutide	VB	dulaglutide	dulaglutide	dulaglutid	N	O
ADAs	NNP	adas	ada	ada	N	O
,	,	,	,	,	N	O
34	CD	34	34	34	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
population	NN	population	population	popul	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
dulaglutide	VBN	dulaglutide	dulaglutide	dulaglutid	N	O
-	:	-	-	-	N	O
neutralizing	NN	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
36	CD	36	36	36	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
population	NN	population	population	popul	N	O
)	)	)	)	)	N	O
developed	VBD	developed	developed	develop	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
against	IN	against	against	against	N	O
native	JJ	native	native	nativ	N	O
GLP	NNP	glp	glp	glp	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
detection	NN	detection	detection	detect	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
formation	NN	formation	formation	format	N	O
is	VBZ	is	is	is	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

Additionally	RB	additionally	additionally	addit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibody	NN	antibody	antibody	antibodi	N	O
)	)	)	)	)	N	O
positivity	NN	positivity	positivity	posit	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
assay	NN	assay	assay	assay	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
dulaglutide	VB	dulaglutide	dulaglutide	dulaglutid	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
.	.	.	.	.	N	O

Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O

Systemic	NNP	systemic	systemic	system	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
severe	JJ	severe	severe	sever	N	B-Severity
(	(	(	(	(	N	O
e	JJ	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	B-Severity
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
systemic	JJ	systemic	systemic	system	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
facial	JJ	facial	facial	facial	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
lip	FW	lip	lip	lip	N	B-AdverseReaction
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
four	CD	four	four	four	N	O
Phase	NNP	phase	phase	phase	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
five	CD	five	five	five	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Injection	NNP	injection	injection	inject	Y	O
-	:	-	-	-	N	O
site	NN	site	site	site	N	O
Reactions	NNS	reactions	reaction	reaction	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	JJ	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	I-AdverseReaction
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
of	IN	of	of	of	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
0.0%	CD	0.0%	0.0%	0.0%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

PR	NNP	pr	pr	pr	N	O
Interval	NNP	interval	interval	interv	N	O
Prolongation	NNP	prolongation	prolongation	prolong	N	O
and	CC	and	and	and	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
First	NNP	first	first	first	N	O
Degree	NNP	degree	degree	degre	N	O
Atrioventricular	NNP	atrioventricular	atrioventricular	atrioventricular	N	O
(	(	(	(	(	N	O
AV	NNP	av	av	av	N	O
)	)	)	)	)	N	O
Block	NNP	block	block	block	N	O

A	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	O
PR	NNP	pr	pr	pr	N	I-AdverseReaction
interval	NN	interval	interval	interv	N	I-AdverseReaction
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
3	CD	3	3	3	N	O
milliseconds	NNS	milliseconds	millisecond	millisecond	N	O
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
contrast	NN	contrast	contrast	contrast	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
decrease	NN	decrease	decrease	decreas	N	O
of	IN	of	of	of	N	O
0.9	CD	0.9	0.9	0.9	N	O
millisecond	NN	millisecond	millisecond	millisecond	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
of	IN	of	of	of	N	O
first	JJ	first	first	first	N	B-AdverseReaction
degree	NN	degree	degree	degre	N	I-AdverseReaction
AV	NNP	av	av	av	N	I-AdverseReaction
block	NN	block	block	block	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
,	,	,	,	,	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
and	CC	and	and	and	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

On	IN	on	on	on	N	O
electrocardiograms	NNS	electrocardiograms	electrocardiogram	electrocardiogram	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
PR	NNP	pr	pr	pr	N	B-AdverseReaction
interval	JJ	interval	interval	interv	N	I-AdverseReaction
increase	NN	increase	increase	increas	N	I-AdverseReaction
to	TO	to	to	to	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
220	CD	220	220	220	N	O
milliseconds	NNS	milliseconds	millisecond	millisecond	N	O
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
,	,	,	,	,	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
and	CC	and	and	and	N	O
3.2%	CD	3.2%	3.2%	3.2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
0.75	CD	0.75	0.75	0.75	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
1.5	CD	1.5	1.5	1.5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Amylase	NNP	amylase	amylase	amylas	Y	O
and	CC	and	and	and	N	O
Lipase	NNP	lipase	lipase	lipas	Y	O
Increase	NNP	increase	increase	increas	N	O

Patients	NNS	patients	patient	patient	N	O
exposed	VBD	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
had	VBD	had	had	had	N	O
mean	VBN	mean	mean	mean	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	I-AdverseReaction
lipase	NN	lipase	lipase	lipas	Y	I-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
pancreatic	JJ	pancreatic	pancreatic	pancreat	N	I-AdverseReaction
amylase	NN	amylase	amylase	amylas	Y	I-AdverseReaction
of	IN	of	of	of	N	O
14%	CD	14%	14%	14%	N	O
to	TO	to	to	to	N	O
20%	CD	20%	20%	20%	N	O
,	,	,	,	,	N	O
while	IN	while	while	while	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
mean	JJ	mean	mean	mean	N	O
increases	NNS	increases	increase	increas	N	O
of	IN	of	of	of	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
3%	CD	3%	3%	3%	N	O
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
OF	IN	of	of	of	N	O
THYROID	NNP	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
CELL	NN	cell	cell	cell	N	I-AdverseReaction
TUMORS	NNP	tumors	tumor	tumor	N	I-AdverseReaction
\n\n\n\n	VBD	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
OF	IN	of	of	of	N	O
THYROID	NNP	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
CELL	NN	cell	cell	cell	N	I-AdverseReaction
TUMORS	NNP	tumors	tumor	tumor	N	I-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
In	IN	in	in	in	N	O
male	NN	male	male	male	N	O
and	CC	and	and	and	N	O
female	JJ	female	female	femal	N	O
rats	NNS	rats	rat	rat	N	B-Animal
,	,	,	,	,	N	O
dulaglutide	JJ	dulaglutide	dulaglutide	dulaglutid	N	O
causes	VBZ	causes	cause	caus	N	O
a	DT	a	a	a	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
duration	NN	duration	duration	durat	N	O
-	:	-	-	-	N	O
dependent	JJ	dependent	dependent	depend	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
(	(	(	(	(	N	O
adenomas	NN	adenomas	adenoma	adenoma	N	I-AdverseReaction
and	CC	and	and	and	N	O
carcinomas	NN	carcinomas	carcinoma	carcinoma	N	I-AdverseReaction
)	)	)	)	)	N	O
after	IN	after	after	after	N	O
lifetime	NN	lifetime	lifetime	lifetim	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	B-Factor
whether	IN	whether	whether	whether	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
causes	VBZ	causes	cause	caus	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
medullary	JJ	medullary	medullary	medullari	N	B-AdverseReaction
thyroid	NN	thyroid	thyroid	thyroid	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
MTC	NNP	mtc	mtc	mtc	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
humans	NNS	humans	human	human	N	O
as	IN	as	a	as	N	O
human	JJ	human	human	human	N	O
relevance	NN	relevance	relevance	relev	N	O
of	IN	of	of	of	N	O
dulaglutide	JJ	dulaglutide	dulaglutide	dulaglutid	N	O
-	:	-	-	-	N	O
induced	JJ	induced	induced	induc	N	O
rodent	NN	rodent	rodent	rodent	N	B-Animal
thyroid	NN	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
determined	VBN	determined	determined	determin	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Nonclinical	NNP	nonclinical	nonclinical	nonclin	N	O
Toxicology	NNP	toxicology	toxicology	toxicolog	N	O
(	(	(	(	(	N	O
13.1	CD	13.1	13.1	13.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

TRULICITY	NNP	trulicity	trulicity	trulic	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
personal	JJ	personal	personal	person	N	O
or	CC	or	or	or	N	O
family	NN	family	family	famili	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Multiple	NNP	multiple	multiple	multipl	N	O
Endocrine	NNP	endocrine	endocrine	endocrin	N	O
Neoplasia	NNP	neoplasia	neoplasia	neoplasia	N	O
syndrome	VBD	syndrome	syndrome	syndrom	N	O
type	JJ	type	type	type	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
MEN	NNP	men	men	men	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Counsel	NNP	counsel	counsel	counsel	N	O
patients	NNS	patients	patient	patient	N	O
regarding	VBG	regarding	regarding	regard	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
with	IN	with	with	with	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
and	CC	and	and	and	N	O
inform	VB	inform	inform	inform	N	O
them	PRP	them	them	them	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
tumors	NNS	tumors	tumor	tumor	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
mass	NN	mass	mass	mass	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
neck	NN	neck	neck	neck	N	O
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	O
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	O
,	,	,	,	,	N	O
persistent	JJ	persistent	persistent	persist	N	O
hoarseness	NN	hoarseness	hoarseness	hoars	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Routine	JJ	routine	routine	routin	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
serum	JJ	serum	serum	serum	N	O
calcitonin	NN	calcitonin	calcitonin	calcitonin	Y	O
or	CC	or	or	or	N	O
using	VBG	using	using	use	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
ultrasound	NN	ultrasound	ultrasound	ultrasound	N	O
is	VBZ	is	is	is	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
value	NN	value	value	valu	N	O
for	IN	for	for	for	N	O
early	JJ	early	early	earli	N	O
detection	NN	detection	detection	detect	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4.1	CD	4.1	4.1	4.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
OF	IN	of	of	of	N	O
THYROID	NNP	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
CELL	NN	cell	cell	cell	N	I-AdverseReaction
TUMORS	NNP	tumors	tumor	tumor	N	I-AdverseReaction
\n	NNP	\n	\n	\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Dulaglutide	NNP	dulaglutide	dulaglutide	dulaglutid	N	O
causes	VBZ	causes	cause	caus	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
in	IN	in	in	in	N	O
rats	NNS	rats	rat	rat	N	B-Animal
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	B-Factor
whether	IN	whether	whether	whether	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
causes	VBZ	causes	cause	caus	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
medullary	JJ	medullary	medullary	medullari	N	B-AdverseReaction
thyroid	NN	thyroid	thyroid	thyroid	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
MTC	NNP	mtc	mtc	mtc	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
humans	NNS	humans	human	human	N	O
as	IN	as	a	as	N	O
the	DT	the	the	the	N	O
human	JJ	human	human	human	N	O
relevance	NN	relevance	relevance	relev	N	O
of	IN	of	of	of	N	O
dulaglutide	JJ	dulaglutide	dulaglutide	dulaglutid	N	O
-	:	-	-	-	N	O
induced	JJ	induced	induced	induc	N	O
rodent	NN	rodent	rodent	rodent	N	B-Animal
thyroid	NN	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
determined	VBN	determined	determined	determin	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
13.1	CD	13.1	13.1	13.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

TRULICITY	NNP	trulicity	trulicity	trulic	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
personal	JJ	personal	personal	person	N	O
or	CC	or	or	or	N	O
family	NN	family	family	famili	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Multiple	NNP	multiple	multiple	multipl	N	O
Endocrine	NNP	endocrine	endocrine	endocrin	N	O
Neoplasia	NNP	neoplasia	neoplasia	neoplasia	N	O
syndrome	VBD	syndrome	syndrome	syndrom	N	O
type	JJ	type	type	type	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
MEN	NNP	men	men	men	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Counsel	NNP	counsel	counsel	counsel	N	O
patients	NNS	patients	patient	patient	N	O
regarding	VBG	regarding	regarding	regard	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
tumors	NNS	tumors	tumor	tumor	N	O
(	(	(	(	(	N	O
4.1	CD	4.1	4.1	4.1	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
\n	$	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Thyroid	NNP	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
Tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
:	:	:	:	:	N	O
See	VB	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
:	:	:	:	:	N	O
Has	NNP	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
promptly	RB	promptly	promptly	promptli	N	O
if	IN	if	if	if	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
restart	VB	restart	restart	restart	N	O
if	IN	if	if	if	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
is	VBZ	is	is	is	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
therapies	NNS	therapies	therapy	therapi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
:	:	:	:	:	N	O
When	WRB	when	when	when	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogue	NN	secretagogue	secretagogue	secretagogu	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
sulfonylurea	NN	sulfonylurea	sulfonylurea	sulfonylurea	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
lowering	VBG	lowering	lowering	lower	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
sulfonylurea	NN	sulfonylurea	sulfonylurea	sulfonylurea	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	O
:	:	:	:	:	N	O
Discontinue	NNP	discontinue	discontinue	discontinu	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
if	IN	if	if	if	N	O
suspected	VBN	suspected	suspected	suspect	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
promptly	RB	promptly	promptly	promptli	N	O
per	IN	per	per	per	N	O
standard	NN	standard	standard	standard	N	O
of	IN	of	of	of	N	O
care	NN	care	care	care	N	O
until	IN	until	until	until	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
resolve	VBP	resolve	resolve	resolv	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
Impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
reporting	NN	reporting	reporting	report	N	O
severe	JJ	severe	severe	sever	N	O
adverse	JJ	adverse	adverse	advers	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
outcomes	NNS	outcomes	outcome	outcom	N	O
:	:	:	:	:	N	O
There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
no	DT	no	no	no	N	O
studies	NNS	studies	study	studi	N	O
establishing	VBG	establishing	establishing	establish	N	O
conclusive	JJ	conclusive	conclusive	conclus	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
risk	NN	risk	risk	risk	N	O
reduction	NN	reduction	reduction	reduct	N	O
with	IN	with	with	with	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
drug	NN	drug	drug	drug	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.1	CD	5.1	5.1	5.1	N	O

Risk	NN	risk	risk	risk	N	O

of	IN	of	of	of	N	O
Thyroid	NNP	thyroid	thyroid	thyroid	N	O
C	NNP	c	c	c	N	O
-	:	-	-	-	N	O
cell	NN	cell	cell	cell	N	O
Tumors	NNS	tumors	tumor	tumor	N	O

In	IN	in	in	in	N	O
male	NN	male	male	male	N	O
and	CC	and	and	and	N	O
female	JJ	female	female	femal	N	O
rats	NNS	rats	rat	rat	N	B-Animal
,	,	,	,	,	N	O
dulaglutide	JJ	dulaglutide	dulaglutide	dulaglutid	N	O
causes	VBZ	causes	cause	caus	N	O
a	DT	a	a	a	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
duration	NN	duration	duration	durat	N	O
-	:	-	-	-	N	O
dependent	JJ	dependent	dependent	depend	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
(	(	(	(	(	N	O
adenomas	NN	adenomas	adenoma	adenoma	N	I-AdverseReaction
and	CC	and	and	and	N	O
carcinomas	NN	carcinomas	carcinoma	carcinoma	N	I-AdverseReaction
)	)	)	)	)	N	O
after	IN	after	after	after	N	O
lifetime	NN	lifetime	lifetime	lifetim	N	O
exposure	NN	exposure	exposure	exposur	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Nonclinical	JJ	nonclinical	nonclinical	nonclin	N	O
Toxicology	NNP	toxicology	toxicology	toxicolog	N	O
(	(	(	(	(	N	O
13.1	CD	13.1	13.1	13.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Glucagon	NNP	glucagon	glucagon	glucagon	Y	O
-	:	-	-	-	N	O
like	IN	like	like	like	N	O
peptide	NN	peptide	peptide	peptid	N	O
(	(	(	(	(	N	O
GLP	NNP	glp	glp	glp	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
receptor	NN	receptor	receptor	receptor	N	O
agonists	NNS	agonists	agonist	agonist	N	O
have	VBP	have	have	have	N	O
induced	VBN	induced	induced	induc	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
adenomas	NN	adenomas	adenoma	adenoma	N	I-AdverseReaction
and	CC	and	and	and	N	O
carcinomas	NN	carcinomas	carcinoma	carcinoma	N	I-AdverseReaction
in	IN	in	in	in	N	O
mice	NN	mice	mouse	mice	N	B-Animal
and	CC	and	and	and	N	O
rats	NNS	rats	rat	rat	N	B-Animal
at	IN	at	at	at	N	O
clinically	RB	clinically	clinically	clinic	N	O
relevant	JJ	relevant	relevant	relev	N	O
exposures	NNS	exposures	exposure	exposur	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	B-Factor
whether	IN	whether	whether	whether	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
will	MD	will	will	will	N	O
cause	VB	cause	cause	caus	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
medullary	JJ	medullary	medullary	medullari	N	B-AdverseReaction
thyroid	NN	thyroid	thyroid	thyroid	N	I-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
(	(	(	(	(	N	O
MTC	NNP	mtc	mtc	mtc	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
humans	NNS	humans	human	human	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
the	DT	the	the	the	N	O
human	JJ	human	human	human	N	O
relevance	NN	relevance	relevance	relev	N	O
of	IN	of	of	of	N	O
dulaglutide	JJ	dulaglutide	dulaglutide	dulaglutid	N	O
-	:	-	-	-	N	O
induced	JJ	induced	induced	induc	N	O
rodent	NN	rodent	rodent	rodent	N	B-Animal
thyroid	NN	thyroid	thyroid	thyroid	N	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
tumors	NNS	tumors	tumor	tumor	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
determined	VBN	determined	determined	determin	N	O
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
patient	NN	patient	patient	patient	N	O
had	VBD	had	had	had	N	O
pretreatment	JJ	pretreatment	pretreatment	pretreat	N	O
calcitonin	NN	calcitonin	calcitonin	calcitonin	Y	O
levels	NNS	levels	level	level	N	O
approximately	RB	approximately	approximately	approxim	N	O
8	CD	8	8	8	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
upper	JJ	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
(	(	(	(	(	N	O
ULN	NNP	uln	uln	uln	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
liraglutide	NN	liraglutide	liraglutide	liraglutid	N	O
,	,	,	,	,	N	O
another	DT	another	another	anoth	N	O
GLP	NNP	glp	glp	glp	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
receptor	NN	receptor	receptor	receptor	N	I-DrugClass
agonist	NN	agonist	agonist	agonist	N	I-DrugClass
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
postmarketing	JJ	postmarketing	postmarketing	postmarket	N	O
period	NN	period	period	period	N	O
;	:	;	;	;	N	O
the	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
reports	NNS	reports	report	report	N	O
are	VBP	are	are	are	N	O
insufficient	JJ	insufficient	insufficient	insuffici	N	O
to	TO	to	to	to	N	O
establish	VB	establish	establish	establish	N	O
or	CC	or	or	or	N	O
exclude	VB	exclude	exclude	exclud	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
between	IN	between	between	between	N	O
MTC	NNP	mtc	mtc	mtc	N	B-AdverseReaction
and	CC	and	and	and	N	O
GLP	NNP	glp	glp	glp	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
receptor	NN	receptor	receptor	receptor	N	O
agonist	NN	agonist	agonist	agonist	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
humans	NNS	humans	human	human	N	O
.	.	.	.	.	N	O

TRULICITY	NNP	trulicity	trulicity	trulic	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
personal	JJ	personal	personal	person	N	O
or	CC	or	or	or	N	O
family	NN	family	family	famili	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
MEN	NNP	men	men	men	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Counsel	NNP	counsel	counsel	counsel	N	O
patients	NNS	patients	patient	patient	N	O
regarding	VBG	regarding	regarding	regard	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
MTC	NNP	mtc	mtc	mtc	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
and	CC	and	and	and	N	O
inform	VB	inform	inform	inform	N	O
them	PRP	them	them	them	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
tumors	NNS	tumors	tumor	tumor	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O

a	DT	a	a	a	N	O
mass	NN	mass	mass	mass	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
neck	NN	neck	neck	neck	N	O
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	O
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	O
,	,	,	,	,	N	O
persistent	JJ	persistent	persistent	persist	N	O
hoarseness	NN	hoarseness	hoarseness	hoars	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Routine	JJ	routine	routine	routin	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
serum	JJ	serum	serum	serum	N	O
calcitonin	NN	calcitonin	calcitonin	calcitonin	Y	O
or	CC	or	or	or	N	O
using	VBG	using	using	use	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
ultrasound	NN	ultrasound	ultrasound	ultrasound	N	O
is	VBZ	is	is	is	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
value	NN	value	value	valu	N	O
for	IN	for	for	for	N	O
early	JJ	early	early	earli	N	O
detection	NN	detection	detection	detect	N	O
of	IN	of	of	of	N	O
MTC	NNP	mtc	mtc	mtc	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
.	.	.	.	.	N	O

Such	JJ	such	such	such	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
unnecessary	JJ	unnecessary	unnecessary	unnecessari	N	O
procedures	NNS	procedures	procedure	procedur	N	O
,	,	,	,	,	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
low	JJ	low	low	low	N	O
test	NN	test	test	test	N	O
specificity	NN	specificity	specificity	specif	N	O
for	IN	for	for	for	N	O
serum	NN	serum	serum	serum	N	O
calcitonin	NN	calcitonin	calcitonin	calcitonin	Y	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
high	JJ	high	high	high	N	O
background	NN	background	background	background	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

Significantly	RB	significantly	significantly	significantli	N	O
elevated	VBN	elevated	elevated	elev	N	O
serum	NN	serum	serum	serum	N	O
calcitonin	NN	calcitonin	calcitonin	calcitonin	Y	O
value	NN	value	value	valu	N	O
may	MD	may	may	may	N	O
indicate	VB	indicate	indicate	indic	N	O
MTC	NNP	mtc	mtc	mtc	N	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
MTC	NNP	mtc	mtc	mtc	N	O
usually	RB	usually	usually	usual	N	O
have	VBP	have	have	have	N	O
calcitonin	VBN	calcitonin	calcitonin	calcitonin	Y	O
values	NNS	values	value	valu	N	O
50	CD	50	50	50	N	O
ng	NNS	ng	ng	ng	N	O
L.	NNP	l.	l.	l.	N	O

If	IN	if	if	if	N	O
serum	JJ	serum	serum	serum	N	O
calcitonin	NN	calcitonin	calcitonin	calcitonin	Y	O
is	VBZ	is	is	is	N	O
measured	VBN	measured	measured	measur	N	O
and	CC	and	and	and	N	O
found	VBN	found	found	found	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
elevated	VBN	elevated	elevated	elev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
further	RB	further	further	further	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
nodules	NNS	nodules	nodule	nodul	N	O
noted	VBN	noted	noted	note	N	O
on	IN	on	on	on	N	O
physical	JJ	physical	physical	physic	N	O
examination	NN	examination	examination	examin	N	O
or	CC	or	or	or	N	O
neck	NN	neck	neck	neck	N	O
imaging	NN	imaging	imaging	imag	N	O
should	MD	should	should	should	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
further	RB	further	further	further	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O

In	IN	in	in	in	N	O
Phase	NNP	phase	phase	phase	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
3.4	CD	3.4	3.4	3.4	N	O
cases	NNS	cases	case	case	N	O
per	IN	per	per	per	N	O
1000	CD	1000	1000	1000	N	O
patient	NN	patient	patient	patient	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
related	JJ	related	related	relat	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
versus	NN	versus	versus	versu	N	O
3	CD	3	3	3	N	O
in	IN	in	in	in	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
incretin	NN	incretin	incretin	incretin	N	O
comparators	NNS	comparators	comparators	compar	N	O
(	(	(	(	(	N	O
2.7	CD	2.7	2.7	2.7	N	O
cases	NNS	cases	case	case	N	O
per	IN	per	per	per	N	O
1000	CD	1000	1000	1000	N	O
patient	NN	patient	patient	patient	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
analyses	NNS	analyses	analysis	analys	N	O
of	IN	of	of	of	N	O
adjudicated	JJ	adjudicated	adjudicated	adjud	N	O
events	NNS	events	event	event	N	O
revealed	VBD	revealed	revealed	reveal	N	O
5	CD	5	5	5	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
confirmed	JJ	confirmed	confirmed	confirm	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
(	(	(	(	(	N	O
1.4	CD	1.4	1.4	1.4	N	O
cases	NNS	cases	case	case	N	O
per	IN	per	per	per	N	O
1000	CD	1000	1000	1000	N	O
patient	NN	patient	patient	patient	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
versus	VBP	versus	versus	versu	N	O
1	CD	1	1	1	N	O
case	NN	case	case	case	N	O
in	IN	in	in	in	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
incretin	NN	incretin	incretin	incretin	N	O
comparators	NNS	comparators	comparators	compar	N	O
(	(	(	(	(	N	O
0.88	CD	0.88	0.88	0.88	N	O
cases	NNS	cases	case	case	N	O
per	IN	per	per	per	N	O
1000	CD	1000	1000	1000	N	O
patient	NN	patient	patient	patient	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
,	,	,	,	,	N	O
observe	NN	observe	observe	observ	N	O
patients	NNS	patients	patient	patient	N	O
carefully	RB	carefully	carefully	care	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
persistent	NN	persistent	persistent	persist	N	O
severe	JJ	severe	severe	sever	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	O
pain	NN	pain	pain	pain	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
promptly	RB	promptly	promptly	promptli	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
is	VBZ	is	is	is	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
,	,	,	,	,	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
restarted	VBN	restarted	restarted	restart	N	O
.	.	.	.	.	N	O

TRULICITY	NNP	trulicity	trulicity	trulic	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
prior	JJ	prior	prior	prior	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
therapies	NNS	therapies	therapy	therapi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Hypoglycemia	NNP	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
Secretagogues	NNP	secretagogues	secretagogues	secretagogu	N	O
or	CC	or	or	or	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
increased	VBN	increased	increased	increas	N	O
when	WRB	when	when	when	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogues	NNS	secretagogues	secretagogues	secretagogu	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
sulfonylureas	JJ	sulfonylureas	sulfonylurea	sulfonylurea	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
sulfonylurea	NN	sulfonylurea	sulfonylurea	sulfonylurea	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
setting	NN	setting	setting	set	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Systemic	NNP	systemic	systemic	system	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reaction	NN	reaction	reaction	reaction	N	O
occurs	VBZ	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
and	CC	and	and	and	N	O
promptly	RB	promptly	promptly	promptli	N	O
seek	VB	seek	seek	seek	N	O
medical	JJ	medical	medical	medic	N	O
advice	NN	advice	advice	advic	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Renal	JJ	renal	renal	renal	N	O
Impairment	NN	impairment	impairment	impair	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
GLP	NNP	glp	glp	glp	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
receptor	NN	receptor	receptor	receptor	N	I-DrugClass
agonists	NNS	agonists	agonist	agonist	N	I-DrugClass
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
and	CC	and	and	and	N	O
worsening	NN	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
chronic	JJ	chronic	chronic	chronic	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
require	VB	require	require	requir	N	O
hemodialysis	NN	hemodialysis	hemodialysis	hemodialysi	Y	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
without	IN	without	without	without	N	O
known	VBN	known	known	known	N	O
underlying	JJ	underlying	underlying	underli	N	O
renal	JJ	renal	renal	renal	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
reported	JJ	reported	reported	report	N	O
events	NNS	events	event	event	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
experienced	VBN	experienced	experienced	experienc	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
may	MD	may	may	may	N	O
worsen	VB	worsen	worsen	worsen	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
,	,	,	,	,	N	O
use	NN	use	use	use	N	O
caution	NN	caution	caution	caution	N	O
when	WRB	when	when	when	N	O
initiating	NN	initiating	initiating	initi	N	O
or	CC	or	or	or	N	O
escalating	VBG	escalating	escalating	escal	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
reporting	NN	reporting	reporting	report	N	O
severe	JJ	severe	severe	sever	N	O
adverse	JJ	adverse	adverse	advers	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
reactions	NNS	reactions	reaction	reaction	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.7	CD	8.7	8.7	8.7	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Severe	NNP	severe	severe	sever	N	O
Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disease	NNP	disease	disease	diseas	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
severe	JJ	severe	severe	sever	N	B-Severity
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

TRULICITY	NNP	trulicity	trulicity	trulic	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
severe	JJ	severe	severe	sever	N	O
gastroparesis	NN	gastroparesis	gastroparesis	gastroparesi	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
is	VBZ	is	is	is	N	O
therefore	RB	therefore	therefore	therefor	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
Outcomes	NNS	outcomes	outcome	outcom	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
no	DT	no	no	no	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
establishing	VBG	establishing	establishing	establish	N	O
conclusive	JJ	conclusive	conclusive	conclus	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
risk	NN	risk	risk	risk	N	O
reduction	NN	reduction	reduction	reduct	N	O
with	IN	with	with	with	N	O
TRULICITY	NNP	trulicity	trulicity	trulic	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

